Malcolm Gladwell talks about scientific discovery in biotech
Malcolm Gladwell spoke last night at this event (Daily coverage is here) about the role of serendipity in drug discovery, focusing on the story of Synta, a biotech company in Boston. The story was later published in his New Yorker column here.
or download the MP3 here.
The approach that Synta is using is essentially high-throughput screening, which is nothing new for the pharmaceutical industry; what’s interesting, though, is seeing combinatorial/high-throughput experimentation techniques starting to be applied to chemistry and materials science – for discovering catalysts, LED phosphors, superconductors, thin-film solar cells, and battery electrodes. Unlike a century ago, when Thomas Edison and his team had to go through 6,000 iterations of light bulb filaments without much scientific understanding to guide them, today there’s simulation software available which can help direct the most promising experiments to conduct – MaterialsGenome and MaterialsStudio come to mind. Companies like Wildcat Discovery and Intermolecular even offer such combinatorial/high-throughput experimentation services, targeted towards the semiconductor and energy industries. What I’d like to see is a hardware platform coupled with open-source software that would allow you to do all the basics – synthesis (sputtering, CVD, or electrodeposition with masks/shutters), processing (inert-gas furnace), analysis (XRD, optical microscopy), and robotic handling for under $10,000.







